

Câncer de Bexiga

Cisplatina + Gencitabina

Cisplatina: 75mg/m ²	IV	D1	
Gencitabina: 1000mg/m ²	IV	D1, D8, D15	
a cada 28 dias			Ref. (1)

Carboplatina + Gencitabina

Carboplatina: AUC 4	IV	D1	
Gencitabina: 1000mg/m ²	IV	D1, D8	
a cada 21 dias			Ref. (2)

Gencitabina + Paclitaxel

Gencitabina: 1000mg/m ²	IV	D1, D8, D15	
Paclitaxel: 200mg/m ²	IV	D1	
a cada 21 dias			Ref. (3)

MVAC

Methotrexate: 30mg/m ²	IV	D1, D15, D22	
Vinblastina: 3mg/m ²	IV	D2, D15, D22	
Doxorrubicina: 30mg/m ²	IV	D2	
Cisplatina: 70mg/m ²	IV	D2	
a cada 28 dias			Ref. (4)

CISCA

Ciclofosfamida: 650mg/m ²	IV	D1	
Adriamicina: 50mg/m ²	IV	D1	
Cisplatina: 100mg/m ²	IV	D2	
a cada 21 dias			Ref. (5)

CMV

Cisplatina: 100mg/m ²	IV	D2
Methotrexate: 30mg/m ²	IV	D1, D8
Vinblastina: 4mg/m ²	IV	D1, D8 a cada 21 dias
Ref. (6)		

Docetaxel + Cisplatina

Docetaxel: 75mg/m ²	IV	D1
Cisplatina: 75mg/m ²	IV	D1 a cada 21 dias

Paclitaxel + Carboplatina

Paclitaxel: 225mg/m ²	IV	D1
Carboplatina: AUC 6	IV	D1 a cada 21 dias
Ref. (7)		

CAP

Ciclofosfamida: 400mg/m ²	IV	D1
Doxorrubicina: 40mg/m ²	IV	D1
Cisplatina: 75mg/m ²	IV	D1 a cada 21 dias
Ref. (8)		

Gencitabina

Gencitabina: 1200mg/m ²	IV	D1, D8, D15
a cada 28 dias		
Ref. (9)		

Paclitaxel

Paclitaxel: 250mg/m ²	IV	D1 em infusão de
24 horas a cada 21 dias		Ref. (10)

OU

Paclitaxel: 80mg/m ²	IV	D1, D8, D15
a cada 28 dias		
Ref. (11)		

Carboplatina + Paclitaxel + Gencitabina

Paclitaxel: 80mg/m² IV D1 e D8

Carboplatina: AUC 5 IV D1

Gencitabina: 800mg/m² IV D1 e D8

a cada 21 dias

Ref. (12)

Cisplatina + Radioterapia

Cisplatina: 100mg/m² IV em 2 aplicações, na 1^o e 4^o semana da Radioterapia.

Radioterapia: dose total de 40 Gy em frações de 180 cGy .

Ref. (13)

Gencitabina + Paclitaxel + Cisplatina

Gencitabina: 1000mg/m² IV D1 e D8

Paclitaxel: 80mg/m² IV D1 e D8

Cisplatina: 70 mg/m² IV D1

a cada 21 dias

Ref. (14)

Pemetrexede

Pemetrexede: 500 mg/m² IV D1 a cada 21 dias

Ref. (15)

Vinflunina

Vinflunina: para pacientes com ECOG PS (0) a dose recomendada é de 320mg/m² durante 20 minutos no D1.

Para pacientes com ECOG PS (1) ou irradiação pélvica prévia iniciar com a dose de 280mg/m² e escalonar até a dose ideal de 320mg/m².

Ref. (16)

1. Kaufman, D., *et al.* Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. *J Clin Oncol*, 2000. 18(9): p. 1921-7.
2. Linardou, H., *et al.* Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. *Urology*, 2004. 64(3): p. 479-84.
3. Meluch, A.A., *et al.* Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. *J Clin Oncol*, 2001. 19(12): p. 3018-24.
4. Sternberg, C.N., *et al.* Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. *Cancer*, 1989. 64(12): p. 2448-58.
5. Logothetis CJ, Dexeus FH, Chong C, *et al.* Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: The M.D. Anderson Experience. *J Urol*. 1989; 141:33-37.
6. Harker, W.G., *et al.* Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. *J Clin Oncol*, 1985. 3(11): p. 1463-70.
7. Vaughn, D.J., *et al.* Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. *Cancer*, 2002. 95(5): p. 1022-7.
8. Okajima E, Ozono S, Hirao Y, *et al.* Neoadjuvant therapy for locally invasive bladder cancer. *Urol Int*. 1989;44 (6):332-337.
9. Moore, M.J., *et al.* Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. *J Clin Oncol*, 1997. 15(12): p. 3441-5.

10. Roth, B.J., *et al.* Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. *J Clin Oncol*, 1994. 12(11): p. 2264-70.
11. Vaughn, D.J., *et al.* Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. *J Clin Oncol*, 2002. 20(4): p. 937-40.
12. White RWV, Lara P, Goldman B, Tangen C, Smith DC, *et al.* A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219). *The Journal of Urology*: 2009; 181;2480-2481
13. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. *J Clin Oncol*. 1999;17(4):1327-8.
14. Bellmunt J, Von der Maase J, Mead GM, Heyer J, Houede N, *et al.* Randomized phase III study comparing paclitaxel/ cisplatin/ gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: LBA5030.
15. Sweeney CJ, *et al.* Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium. *J Clin Oncol* 2006;24:3451-57
16. Bellmunt J, Theodore C, DemKov T, Komyakov B, Sengelov L, Daugaard G, Caty A, *et al.* Phase III Trial of Vinflunine Plus Best Supportive Care Compared with Best Supportive Care Alone After Platinum Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract (TCCU). *J Clin Oncol* 2009; 27: 4454-4461.